NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Lupin Q4 FY26 Net Profit Surges 89% YoY to ₹1,460 Cr; US Sales Grow 55%
Lupin reported a stellar performance for Q4 FY26, with net sales growing 33% YoY to ₹7,392 crore and net income jumping 89% to ₹1,460 crore. The growth was primarily driven by the North American market, which saw a 55% YoY revenue increase, and a strong 12% growth in the domestic India business. EBITDA margins expanded significantly to 29.4% from 23.2% a year ago, reflecting improved operational efficiency. The company also achieved a net cash position with a net debt-to-equity ratio of -0.21.
முக்கிய அம்சங்கள்
Q4 FY26 Net Income rose 89% YoY to ₹14,604 mn, while EBITDA grew 68% to ₹21,711 mn.North America sales surged 55% YoY to ₹35,145 mn, driven by new product launches and complex generics.India business grew 12% YoY to ₹19,082 mn, outperforming the market in Cardiology and Respiratory segments.EBITDA margins improved to 29.4% in Q4 FY26 compared to 23.2% in Q4 FY25.Company turned net cash positive with a net debt-to-equity ratio of -0.21 as of March 31, 2026.
👀 கவனிக்க வேண்டியவை
Investors should view this as a strong performance, particularly the massive margin expansion and US market recovery. The focus on complex generics and biosimilars provides a healthy long-term outlook.
Lupin Q4 FY26 PAT Jumps 88% YoY to ₹14,687 Mn; EBITDA Margins Expand to 35.5%
Lupin reported a stellar performance for Q4 FY2026, with consolidated revenue growing 32.9% YoY to ₹73,919 Mn. Net profit for the quarter surged 87.7% YoY to ₹14,687 Mn, driven by robust growth in the US market (up 56.9%) and significant margin expansion. The Board recommended a high dividend of 900%, reflecting strong cash flows and a net cash position of ₹46,358 Mn. Full-year FY26 revenue and PAT also showed strong double-digit growth of 23.9% and 62.0% respectively.
முக்கிய அம்சங்கள்
Q4 FY26 EBITDA surged 90.6% YoY to ₹26,263 Mn with margins expanding by 1070 bps to 35.5%.US sales grew 56.9% YoY to ₹33,987 Mn, now accounting for 46% of total global sales.India formulation sales grew 14.5% in Q4, maintaining Lupin's position as the 8th largest player in the domestic market.The company turned net debt-free with a net cash balance of ₹46,358 Mn as of March 31, 2026.Recommended a dividend of 900% for the fiscal year based on a strong long-term outlook.
👀 கவனிக்க வேண்டியவை
The significant margin expansion and robust US growth make Lupin a strong pick in the pharma sector. Investors should maintain their positions as the company leverages its net cash status for future growth and complex generic launches.
Lupin Recommends ₹18 Dividend; FY26 Net Profit Jumps 60% to ₹63,666 Million
Lupin Limited has recommended a final dividend of ₹18 per share for the financial year ended March 31, 2026, representing a 900% payout on its face value. The company reported a robust annual performance with total revenue from operations growing 15% to ₹195,126.6 million. Net profit for the year saw a significant surge of 60.2%, reaching ₹63,665.6 million compared to ₹39,729.6 million in FY25. This growth was bolstered by strong operational margins and a net exceptional gain of ₹4,065.7 million from business divestments.
முக்கிய அம்சங்கள்
Recommended a final dividend of ₹18 per equity share of face value ₹2 each.Annual revenue from operations increased 15% YoY to ₹195,126.6 million.Net profit after tax surged 60.2% YoY to ₹63,665.6 million for FY26.Basic Earnings Per Share (EPS) rose significantly to ₹139.38 from ₹87.10 in the previous year.Recorded a net exceptional gain of ₹4,065.7 million, primarily driven by the divestment of OTC and API R&D businesses.
👀 கவனிக்க வேண்டியவை
Investors should consider the strong earnings growth and high dividend payout as a positive indicator of the company's financial health. The stock remains attractive for dividend-seeking investors, though one should monitor the ongoing legal settlements mentioned in the notes.
Lupin Receives US FDA Approval for Glycerol Phenylbutyrate Oral Liquid ($337M Market)
Lupin Limited has secured US FDA approval for its generic version of Ravicti® (Glycerol Phenylbutyrate Oral Liquid, 1.1 g/mL). The drug is used for the chronic management of urea cycle disorders (UCDs) in patients who cannot be managed by diet alone. According to IQVIA MAT December 2025 data, the reference product had annual sales of approximately USD 337 million in the United States. This approval marks a significant addition to Lupin's complex generic portfolio in the US market.
முக்கிய அம்சங்கள்
Received US FDA approval for Glycerol Phenylbutyrate Oral Liquid, 1.1 grams per mL.Product is bioequivalent to the reference drug Ravicti® from Horizon Therapeutics.Target market size for the product is estimated at USD 337 million based on 2025 sales data.Indicated for patients with urea cycle disorders (UCDs) requiring chronic management.Strengthens Lupin's position in the US generic formulations and specialty therapy segments.
👀 கவனிக்க வேண்டியவை
Investors should monitor the commercial launch timeline and Lupin's ability to capture market share in this $337 million niche segment. This approval supports the company's growth outlook for its US business in the 2026-27 fiscal period.
Lupin Launches Generic Xigduo XR Tablets in the United States
Lupin Limited has announced the launch of Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets in the U.S. market. This product is a generic version of AstraZeneca's Xigduo XR, indicated for the treatment of type 2 diabetes. The launch follows the approval of Lupin's Abbreviated New Drug Application (ANDA) by the U.S. FDA. This expansion strengthens Lupin's existing anti-diabetic portfolio in its key U.S. market.
முக்கிய அம்சங்கள்
Launch of generic Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets in the U.S.Product is bioequivalent to AstraZeneca's Xigduo XRAvailable in four strengths: 5 mg/500 mg, 5 mg/1,000 mg, 10 mg/500 mg, and 10 mg/1,000 mgStrengthens Lupin's position in the U.S. anti-diabetic therapy segment
👀 கவனிக்க வேண்டியவை
Investors should monitor the ramp-up of this product as it contributes to Lupin's U.S. generic revenue stream. The successful launch of complex generics and chronic therapy products remains a key growth driver for the company.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Lupin's Somerset Facility Receives US FDA Form-483 with 3 Observations
The U.S. FDA conducted an inspection of Lupin's manufacturing facility in Somerset, New Jersey, from April 13 to April 17, 2026. The inspection concluded with the issuance of a Form-483 containing three observations. Lupin has committed to addressing these observations and responding to the regulator within the stipulated timeframe. While the number of observations is relatively low, the company's ability to resolve them without further escalation is critical for its U.S. operations.
முக்கிய அம்சங்கள்
Inspection conducted at the Somerset, New Jersey facility from April 13 to April 17, 2026U.S. FDA issued a Form-483 with 3 specific observations upon conclusion of the auditLupin is required to submit a formal response to the observations within the regulatory timeframeThe facility's compliance status is vital for maintaining current supply and future product approvals in the U.S. market
👀 கவனிக்க வேண்டியவை
Investors should monitor for the FDA's final classification of the inspection; while 3 observations are manageable, any escalation to an OAI status could impact the stock's valuation.
Lupin Subsidiary Settles US Antitrust Lawsuit with Humana for USD 30 Million
Lupin's US subsidiary, Lupin Pharmaceuticals, Inc. (LPI), has entered into a settlement agreement with Humana Inc. to resolve civil lawsuits alleging anticompetitive behavior. Under the agreement, LPI will pay USD 30 million to settle all claims related to the 'In Re Generic Pharmaceuticals Antitrust Litigation'. Crucially, the company stated that this settlement amount has already been provided for in prior consolidated financial results, meaning no new impact on current earnings. The settlement allows Lupin to avoid the costs and uncertainties of continued litigation while maintaining its denial of any liability.
முக்கிய அம்சங்கள்
Lupin Pharmaceuticals, Inc. USA to pay USD 30 million to Humana Inc. as part of a settlement agreement.The settlement amount was already accounted for in the company's previous consolidated financial statements.The litigation involved allegations of federal and state antitrust law violations in the US generic market.Agreement provides a full and final release of all claims against LPI, its parents, affiliates, and officers.LPI continues to deny all allegations and the settlement does not imply admission of liability.
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive resolution of a legal overhang, particularly as the financial impact was already provisioned. No immediate action is required as the settlement does not affect future cash flows beyond what was already anticipated.
Lupin Launches Generic Dapagliflozin Tablets (5 mg and 10 mg) in the United States
Lupin Limited has announced the commercial launch of Dapagliflozin Tablets in the United States market in 5 mg and 10 mg strengths. This launch follows the U.S. FDA approval of Lupin's Abbreviated New Drug Application (ANDA), establishing the product as a bioequivalent to AstraZeneca's Farxiga®. The product targets the anti-diabetic segment, which is a core therapeutic area for Lupin. This move is expected to strengthen Lupin's generic portfolio and revenue potential in the North American market.
முக்கிய அம்சங்கள்
Launch of Dapagliflozin Tablets in 5 mg and 10 mg strengths in the US market.Received U.S. FDA approval for ANDA as a bioequivalent to the reference brand Farxiga®.Strengthens Lupin's position in the anti-diabetic therapy area across its 100+ global markets.The launch leverages Lupin's extensive infrastructure of 15 manufacturing sites and 7 research centers.
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive development for Lupin's US generic business. Monitor the company's upcoming quarterly results for the revenue contribution and market share gains from this specific launch.
Lupin Receives U.S. FDA Approval for Generic Xigduo XR Tablets
Lupin Limited has received U.S. FDA approval for its Abbreviated New Drug Application (ANDA) for Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets. The approval covers four specific strengths: 5 mg/500 mg, 5 mg/1,000 mg, 10 mg/500 mg, and 10 mg/1,000 mg. Additionally, the company received tentative approval for the 2.5 mg/1,000 mg strength. This product is a bioequivalent version of AstraZeneca's Xigduo XR, targeting the significant anti-diabetic market in the United States.
முக்கிய அம்சங்கள்
Received U.S. FDA approval for four strengths of Dapagliflozin and Metformin Hydrochloride ER TabletsObtained tentative approval for the 2.5 mg/1,000 mg strength of the same formulationProduct is a generic version of AstraZeneca's Xigduo XR, a major branded anti-diabetic drugStrengthens Lupin's presence in the U.S. market for chronic therapy areas like diabetesLupin operates 15 manufacturing sites and 7 research centers globally to support such launches
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive step in Lupin's U.S. generic strategy, likely contributing to revenue growth in the anti-diabetic segment. Monitor the commercial launch timeline and potential market share capture from the innovator.
Lupin Completes Acquisition of VISUfarma; Adds €53m Revenue Portfolio
Lupin Limited has successfully completed the acquisition of VISUfarma B.V., a European specialty pharmaceutical firm focused on ophthalmology. The acquisition brings over 60 branded products into Lupin's portfolio, covering areas like dry eye, glaucoma, and retinal health. VISUfarma reported revenues of €53 million in 2025 and maintains a strong commercial presence in Italy, the UK, Spain, Germany, and France. This strategic move is expected to be immediately accretive to Lupin's earnings and significantly strengthens its specialty care footprint in the European market.
முக்கிய அம்சங்கள்
Acquisition adds a portfolio of over 60 branded ophthalmology products across EuropeVISUfarma generated €53 million in revenue during the 2025 calendar yearExpands Lupin's commercial footprint in 5 major European markets: Italy, UK, Spain, Germany, and FranceManagement confirms the acquisition is immediately accretive to the company's financial performance
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive strategic expansion into high-margin specialty segments. Monitor the integration progress and the incremental contribution to the European business segment in upcoming quarterly results.
Lupin to Acquire 43.38% Stake in Multicare Philippines for USD 39.6 Million
Lupin's subsidiary, Nanomi B.V., has signed a definitive agreement to acquire a 43.38% minority stake in Multicare Pharmaceuticals Philippines, Inc. (MPPI) for a cash consideration not exceeding USD 39.6 million. Nanomi already holds a 56.28% stake in the entity, and this acquisition is a strategic move to eventually make MPPI a wholly-owned subsidiary. MPPI is a key player in the Philippines pharmaceutical market, reporting a turnover of PHP 2,096.6 million for FY25. The transaction is expected to be completed by May 2026, facilitating better operational integration and strategic flexibility in emerging markets.
முக்கிய அம்சங்கள்
Acquisition of 11,794,497 shares representing 43.38% of the total paid-up shares of MPPI.Total cash consideration for the minority stake is capped at USD 39.6 million.MPPI reported a turnover of PHP 2,096.6 million and a net worth of PHP 1,265.5 million as of March 31, 2025.The deal aims to consolidate Lupin's presence in the Philippines and unlock long-term value through full ownership.
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive consolidation move that strengthens Lupin's emerging market portfolio. Monitor the completion of the deal by May 2026 and its subsequent impact on consolidated bottom-line growth.
Lupin Completes Acquisition of Netherlands-based VISUfarma B.V.
Lupin Limited, through its wholly owned subsidiary Nanomi B.V., has successfully completed the acquisition of 100% share capital of VISUfarma B.V., Netherlands. The deal, which was initially announced in September 2025, reached completion on April 1, 2026, after fulfilling all customary closing conditions. Consequently, VISUfarma and its subsidiaries have now become wholly owned step-down subsidiaries of Lupin. This acquisition is expected to bolster Lupin's footprint in the European pharmaceutical market.
முக்கிய அம்சங்கள்
Acquisition of 100% share capital of VISUfarma B.V. finalized on April 1, 2026Transaction executed via Nanomi B.V., a wholly owned subsidiary of Lupin LimitedVISUfarma and its subsidiaries are now step-down subsidiaries of the companyFollows a series of regulatory updates starting from the definitive agreement in September 2025
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive step in Lupin's international expansion strategy and monitor the subsequent impact on European revenue. No immediate action is required, but the integration of VISUfarma's portfolio will be a key metric to watch in upcoming quarterly results.
Lupin Receives Tentative U.S. FDA Approval for Sugammadex Injection
Lupin Limited has received tentative approval from the U.S. FDA for its Abbreviated New Drug Application for Sugammadex Injection, available in 200 mg/2 mL and 500 mg/5 mL strengths. The product is a generic version of Merck's Bridion, used to reverse neuromuscular blockade in surgical patients aged 2 years and older. While a tentative approval indicates the product meets safety and efficacy standards, it cannot be marketed until patent or exclusivity issues are resolved. This approval strengthens Lupin's future injectable pipeline in the critical U.S. hospital segment.
முக்கிய அம்சங்கள்
Received tentative U.S. FDA approval for Sugammadex Injection (200 mg/2 mL and 500 mg/5 mL).Product is bioequivalent to Merck’s Bridion Injection, a major brand in the neuromuscular reversal market.Indicated for use in both adult and pediatric patients (2 years and older) undergoing surgery.Expands Lupin's portfolio of complex generics and injectable products for the U.S. market.Approval covers single-dose vials of 100 mg/mL concentration.
👀 கவனிக்க வேண்டியவை
Investors should monitor for the transition from tentative to final approval, which will depend on the expiration of innovator patents. This development is a positive indicator of Lupin's R&D capabilities in the complex injectable space.
Lupin Increases Stake in Philippines Subsidiary MPPI to 56.28% via Buyback
Lupin Limited's indirect subsidiary, Multicare Pharmaceuticals Philippines, Inc. (MPPI), has completed a buyback of 2,813,811 equity shares from existing shareholders. Lupin's intermediate holding company, Nanomi B.V., did not participate in the buyback, resulting in its stake in MPPI increasing from 51% to 56.28%. MPPI is a profitable entity with a FY25 turnover of PHP 2,096.6 million. This consolidation of ownership was funded through MPPI's retained earnings, requiring no cash outflow from Lupin.
முக்கிய அம்சங்கள்
Indirect shareholding in MPPI increased from 51% to 56.28% effective March 30, 2026.MPPI bought back 2,813,811 equity shares using its own retained earnings.MPPI reported a turnover of PHP 2,096.6 million and Net Worth of PHP 1,265.5 million for FY25.The transaction results in higher earnings consolidation for Lupin without any fresh capital investment.
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive structural move that increases Lupin's exposure to the Philippines market without capital expenditure. No immediate action is required, but it strengthens the company's long-term consolidated bottom line.
Lupin Receives U.S. FDA Tentative Approval for Pitolisant Tablets (Generic Wakix)
Lupin Limited has secured tentative approval from the U.S. FDA for its Pitolisant Tablets in 4.45mg and 17.8mg strengths. This product is a generic version of Wakix, which is indicated for the treatment of narcolepsy. The tablets will be manufactured at Lupin's Nagpur facility in India. While the approval is tentative, it marks a significant step in expanding Lupin's CNS portfolio in the U.S. market.
முக்கிய அம்சங்கள்
Received tentative U.S. FDA approval for Pitolisant Tablets (4.45mg and 17.8mg)Product is bioequivalent to the reference brand drug Wakix®Manufacturing will be localized at the company's Nagpur facility in IndiaStrengthens Lupin's presence in the U.S. Central Nervous System (CNS) therapy segment
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive development for Lupin's medium-term U.S. pipeline, though they should wait for clarity on the final approval and launch timeline. Monitor the stock for potential gains as the company moves closer to commercializing this narcolepsy treatment.
Lupin Subsidiary LMS Expands Dabhasa Facility to Boost Peptide and CRDMO Capabilities
Lupin Manufacturing Solutions (LMS), a wholly-owned subsidiary of Lupin, has announced a strategic expansion of its Dabhasa facility in India to scale its peptide building-blocks platform. The expansion includes a new block for CRDMO services and two specialized units dedicated to peptide manufacturing. This move targets the high-growth market for complex therapeutics, including peptides and Antibody-Drug Conjugates (ADCs). By strengthening its infrastructure, Lupin aims to capture a larger share of the global advanced pharmaceutical solutions market through its team of over 250 scientists.
முக்கிய அம்சங்கள்
Strategic expansion of Dabhasa facility to scale peptide building-blocks and CRDMO capabilities.Addition of a new CRDMO block and two specialized units for dedicated peptide manufacturing.Focus on complex modalities including protected amino acids, peptides, and biologic ADCs.LMS leverages a team of over 250 scientists to support early development to commercial scale.Strengthens Lupin's position in the global peptide ecosystem and complex therapeutics market.
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive long-term move to diversify into high-margin CDMO and complex generic segments. Monitor the revenue contribution from the LMS subsidiary in upcoming quarters to gauge the execution and scaling of this expansion.
Lupin and Zydus Sign Licensing Deal to Co-market Semaglutide Injection in India
Lupin Limited has entered into a licensing and supply agreement with Zydus Lifesciences to co-market Semaglutide Injection (15 mg/3 ml) in the Indian market. Under the agreement, Lupin will market the product under the brands Semanext and Livarise, while Zydus will continue with its own brands. Lupin is required to pay Zydus upfront licensing fees and milestone-based payments for these semi-exclusive rights. This partnership targets the high-growth segments of Type 2 diabetes and chronic weight management in India.
முக்கிய அம்சங்கள்
Lupin gains semi-exclusive rights to co-market Zydus's innovative Semaglutide Injection (15 mg/3 ml) in India.Lupin will market the therapy under brand names Semanext and Livarise using a reusable pen device.The agreement involves Lupin paying Zydus upfront licensing fees and milestone payments.Therapy targets Type 2 diabetes and obesity management for adults with BMI of 30 kg/m2 or greater.The partnership leverages Lupin's extensive domestic reach to expand access to GLP-1 therapies.
👀 கவனிக்க வேண்டியவை
Investors should view this as a strategic positive as it strengthens Lupin's cardio-metabolic portfolio with a high-demand GLP-1 therapy. Monitor the market share gains and the impact of milestone payments on Lupin's margins in the coming quarters.
Lupin's Ankleshwar Facility Receives US FDA Form-483 with 2 Observations
The U.S. FDA concluded a six-day inspection at Lupin's manufacturing facility in Ankleshwar, India, on March 07, 2026. The inspection resulted in the issuance of a Form-483 with two observations regarding manufacturing practices. Lupin has stated it will address these observations and respond to the regulator within the stipulated timeframe to ensure CGMP compliance. While the number of observations is low, the impact depends on their technical severity and the company's ability to remediate them quickly.
முக்கிய அம்சங்கள்
U.S. FDA inspection conducted at the Ankleshwar facility from March 02 to March 07, 2026.The inspection concluded with the issuance of a Form-483 containing 2 observations.Lupin is required to respond to the U.S. FDA within the stipulated timeframe to address findings.Company maintains commitment to CGMP standards across all manufacturing facilities.
👀 கவனிக்க வேண்டியவை
Investors should monitor for the final classification of the inspection (VAI or OAI) as significant observations could lead to regulatory escalations. The low number of observations is generally manageable, but the specific nature of the findings will determine the long-term impact on US exports.
Lupin Delays Acquisition of VISUfarma B.V. to April 2026
Lupin Limited has announced a timeline extension for the acquisition of VISUfarma B.V. by its subsidiary, Nanomi B.V. The transaction, which involves acquiring 100% of the share capital, was previously expected to conclude by February 28, 2026. The company now anticipates completion in April 2026, pending the satisfaction of specific closing conditions. This acquisition is a strategic move to strengthen Lupin's presence in the European pharmaceutical market.
முக்கிய அம்சங்கள்
Acquisition of 100% share capital of Netherlands-based VISUfarma B.V. by Lupin's subsidiary Nanomi B.V.Completion timeline extended from February 28, 2026, to April 2026.Delay is attributed to the ongoing fulfillment of specific closing conditions.Follows previous regulatory updates provided on September 29, 2025, and December 30, 2025.
👀 கவனிக்க வேண்டியவை
Investors should view this as a minor procedural delay rather than a deal cancellation. Monitor for the final completion announcement in April 2026 to assess the impact on Lupin's international revenue growth.
Lupin Receives US FDA EIR with Satisfactory VAI Status for Goa Facility
Lupin Limited has successfully received the Establishment Inspection Report (EIR) from the US FDA for its Goa manufacturing facility. The report follows an 11-day inspection conducted from November 10 to November 21, 2025. The facility has been assigned a Voluntary Action Indicated (VAI) classification, which is considered a satisfactory regulatory outcome. This clearance is crucial for Lupin as it ensures the continued supply and potential for new product approvals from this key export site to the US market.
முக்கிய அம்சங்கள்
Received US FDA EIR for the Goa facility with a satisfactory VAI classification.The inspection was conducted over an 11-day period from November 10 to November 21, 2025.VAI status indicates that the facility meets regulatory standards despite minor observations.This clearance supports Lupin's global supply chain and US market growth strategy.
👀 கவனிக்க வேண்டியவை
This is a positive development that removes a significant regulatory overhang for the Goa plant. Investors should monitor for potential new product approvals from this site that may have been pending the inspection outcome.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
